Evidence map›Paper›PMID 39777970›Full record

ArticleChembiochem : a European journal of chemical biology2025

Modulation of CRISPR-Cas9 Cleavage with an Oligo-Ribonucleoprotein Design.

Yahui Gao, Yan Shan Ang, Lin-Yue Lanry Yung

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Modulation of CRISPR-Cas9 Cleavage with an Oligo-Ribonucleoprotein Design.Chembiochem : a European journal of chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yahui GaoDepartment of Chemical & Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore.
Yan Shan AngDepartment of Chemical & Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore.
Lin-Yue Lanry YungDepartment of Chemical & Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore.ORCID https://orcid.org/0000-0001-7579-6347

Funding

Tier 1 A-0009534-01-00Tier 2 MOE-T2EP50120-0018
6 · The paper itself

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) associated protein Cas9 system has been widely used for genome editing. However, the editing or cleavage specificity of CRISPR Cas9 remains a major concern due to the off-target effects. The existing approaches to control or modulate CRISPR Cas9 cleavage include engineering Cas9 protein and development of anti-CRISPR proteins. There are also attempts on direct modification of sgRNA, for example, structural modification via truncation or hairpin design, or chemical modification on sgRNA such as partially replacing RNA with DNA. The above-mentioned strategies rely on extensive protein engineering and direct chemical or structural modification of sgRNA. In this study, we proposed an indirect method to modulate CRISPR Cas9 cleavage without modification on Cas9 protein or sgRNA. An oligonucleotide was used to form an RNA-DNA hybrid structure with the sgRNA spacer, creating steric hindrance during the Cas9 mediated DNA cleavage process. We first introduced a simple and robust method to assemble the oligo-ribonucleoprotein (oligo-RNP). Next, the cleavage efficiency of the assembled oligo-RNP was examined using different oligo lengths in vitro. Lastly, we showed that the oligo-RNP directly delivered into cells could also modulate Cas9 activity inside cells using three model gene targets with reduced off-target effects.

Indexed as

CRISPR-Associated Protein 9CRISPR-Cas SystemsOligonucleotidesRibonucleoproteinsDNADNA CleavageGene EditingHEK293 CellsHumansRNA, Guide, CRISPR-Cas SystemsCRISPR-Associated Protein 9DNAOligonucleotidesRibonucleoproteinsRNA, Guide, CRISPR-Cas SystemsCRISPR Cas9DNADNA cleavagegenome editingmodulation of Cas9

Identifiers

PMID39777970
PMCPMC11833760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.